Current Strategies for the Treatment of Hereditary Tyrosinemia Type I
- 98 Downloads
Hereditary tyrosinemia type I (HT-I) is the most common of the three known diseases caused by defects in tyrosine metabolism. This type of tyrosinemia is caused by a mutation in the gene coding for fumarylacetoacetate hydrolase; several mutations in this gene have been identified. The main clinical features of HT-I are caused by hepatic involvement and renal tubular dysfunction.
Dietary intervention with restriction of phenylalanine and tyrosine together with supportive measures can ameliorate the symptoms, but given the high risk for hepatocellular carcinoma, a cure for these patients has so far been possible only with liver transplantation.
Pharmacologic treatment with nitisinone, a peroral inhibitor of the tyrosine catabolic pathway, offers an improved means of treatment for patients with HT-I. However, longer follow-up periods are needed to establish the role of this drug in ultimately protecting patients from end-stage organ involvement and hepatocellular carcinoma. Experimental work in mice has provided some promise for the future management of tyrosinemia with gene therapy.
This work was supported by the Finnish Pediatric Foundation and the Helsinki University Central Hospital and Tampere University Hospital research funds. The authors have no conflicts of interest that are directly relevant to the content of this review.
- 3.Nyhan WL, Ozand PT. Tyrosinemia. In: Nyhan WL, Ozand PT, editors. Atlas of metabolic diseases. London: Chapman and Hall Medical, 1998: 153–9Google Scholar
- 12.Rootwelt H, Brodtkorb E, Kvittingen EA. Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications of diagnosis of tyrosinemia type I. Am J Genet 1994; 55: 1122–7Google Scholar
- 20.Hermes-Lima M, Valle VGR, Vercesi AE, et al. Damage to rat liver mithochondria promoted by delta-aminolevulinic acid-generated reactive oxygen species: connections with acute intermittent porphyria and lead poisoning. Biochim Biophys Acta 1991; 105: 57–63Google Scholar
- 26.Labergne C. Hereditary tyrosinemia in a French Canadian isolate. Am J Hum Genet 1969; 21: 36–45Google Scholar
- 31.Kvittingen EA, Brodtkorb E. The pre- and post-natal diagnosis of tyrosinemia type I and the detection of the carrier state by assay of fumarylacetoacetase. Scand J Clin Lab Invest 1986; 184: 35–40Google Scholar
- 47.Holme E, Lindstedt S, Lock EA. Treatment of tyrosinemia type I with an enzyme inhibitor (NTBC). Int Pediatr 1995; 10: 41–3Google Scholar
- 54.Shaw V, Lawson M, editors. Tyrosinaemia type I, in clinical paediatric dietetics. 2nd ed. London: Blackwell Science, 2001: 241–62Google Scholar